Cancer drug resistance

The in vitro system has some limitations and it can be used only as a model to address acquired drug resistance, because cell lines may not accurately reflect the in vivo situation of patients treated with anticancer drugs. In vivo analysis using patient samples to study anti-cancer drug resistance are described in the published literature. Chang and coworkers (64) showed that the gene-expression patterns from mRNA derived from needle biopsies of breast cancer patients treated with the anticancer drug, docetaxel, could be predictive of response to the therapy. 

Weinberg OK, Marquez-Garban DC, Pietras RJ. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Update. 2005 8 219-233. 

Chen JY, Shen C, Yan Z, Brown DP, Wang M. A systems biology case study of ovarian cancer drug resistance. Comput Syst Bioinformatics Conf. 2006 389-398. 

Ross DD, Doyle LA. Mining our ABCs Pharmacoge-nomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 2004 6 129-37. 

GottesmanMM. Mechanisms of cancer drug resistance. Ann Rev Med2002 53 615-627. 

Vogel, G. M., 2003, Combating cancer-drug resistance The ceramide connection. Phi Kappa Phi Forum 83(1) 20-24 (Fall). 

Eloyle LA, Kaufman SH, Fojo AT, Bailey CL, Gaidar AF. A novel 95 kilodalion membrane polypeptide associated with lung cancer drug resistance. Lung Cancer 1993 9 317-326-... 

D.S. Tan, M. Gerlinger, B.T. Teh, C. Swanton, Anti-cancer drug resistance understanding the mechanisms through the use of integrative genomics and functional RNA interference, Eur. J. Cancer 46 (2010) 2166-2177. 

Bonavida, B., Khineche, S., Huerta-Yepez, S., and Garban, H. (2006). Therapeutic potential of nitric oxide in cancer. Drug Resist. Updat. 9,157-173. 

Townsend, D.M. and Tew, K.D. (2003b). The role of glutathione-5-transferase in anti-cancer drug resistance. Oncogene 22, 7369-7375. 

---